Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Milutinovic M, Thaçi D. Blauvelt A, et al. Among authors: ziv m. J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9. doi: 10.1016/j.jaad.2016.08.008. Epub 2016 Sep 20. J Am Acad Dermatol. 2017. PMID: 27663079 Clinical Trial.
Pregnancy outcomes in women with moderate-to-severe psoriasis.
Cohen-Barak E, Nachum Z, Rozenman D, Ziv M. Cohen-Barak E, et al. Among authors: ziv m. J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1041-7. doi: 10.1111/j.1468-3083.2010.03917.x. Epub 2010 Nov 25. J Eur Acad Dermatol Venereol. 2011. PMID: 21108670
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M. Thaçi D, et al. Among authors: ziv m. J Am Acad Dermatol. 2015 Sep;73(3):400-9. doi: 10.1016/j.jaad.2015.05.013. Epub 2015 Jun 17. J Am Acad Dermatol. 2015. PMID: 26092291 Free article. Clinical Trial.
Impact of antipsoriatic therapy on endothelial function.
Cohen-Barak E, Sah M, Kerner M, Rozenman D, Ziv M. Cohen-Barak E, et al. Among authors: ziv m. Br J Dermatol. 2015 Dec;173(6):1440-6. doi: 10.1111/bjd.14076. Epub 2015 Nov 1. Br J Dermatol. 2015. PMID: 26280258
Biologic drug survival in Israeli psoriasis patients.
Shalom G, Cohen AD, Ziv M, Eran CB, Feldhamer I, Freud T, Berman E, Oren S, Hodak E, Pavlovsky L. Shalom G, et al. Among authors: ziv m. J Am Acad Dermatol. 2017 Apr;76(4):662-669.e1. doi: 10.1016/j.jaad.2016.10.033. Epub 2016 Dec 28. J Am Acad Dermatol. 2017. PMID: 28038888
Wells' Syndrome Induced by Ustekinumab.
Rozenblat M, Cohen-Barak E, Dodiuk-Gad R, Ziv M. Rozenblat M, et al. Among authors: ziv m. Isr Med Assoc J. 2019 Jan;21(1):65. Isr Med Assoc J. 2019. PMID: 30685913 Free article. No abstract available.
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.
Thaçi D, Puig L, Reich K, Tsai TF, Tyring S, Kingo K, Ziv M, Pinter A, Vender R, Lacombe A, Xia S, Bhosekar V, Gilloteau I, Guana A, Blauvelt A. Thaçi D, et al. Among authors: ziv m. J Am Acad Dermatol. 2019 Dec;81(6):1405-1409. doi: 10.1016/j.jaad.2019.04.045. Epub 2019 Aug 6. J Am Acad Dermatol. 2019. PMID: 31399223 Free article. Clinical Trial. No abstract available.
173 results